Loading stock data…
GERN
$1.41+0.01 (+0.71%)
Pre-Market$1.41+0.00 (+0.00%)· Last close May 13
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Geron Corporation in the Healthcare sector is trading at $1.41. Wall Street consensus targets $3.40 (5 analysts), implying a +141.1% move over the next 12 months. The stock is currently 30% below its 52-week high of $2.01, remaining 0.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +141.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$1.41
Potential Downside
0%
Whystock Fair Value$1.41
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Buy
Mean target$3.40+141.1%
Range$1.00 – $5.00
Fundamentals
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$993.40M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.67
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-58.12%
Volume
Today's trading volume
25.08M
Recent News
Is Geron (GERN) One of the Best US Stocks Under $5 to Buy?
Geron Corporation (NASDAQ:GERN) is one of the 10 Best US Stocks Under $5 to Buy. On May 7, Wedbush reiterated its Outperform rating on Geron Corporation (NASDAQ:GERN) with a price target of $5 on the stock. This update comes after the company reported results for the first quarter of 2026 and recent business developments. During […]
A Look At Geron (GERN) Valuation After Q1 Results And Reaffirmed 2026 Guidance
Geron (GERN) has put its first quarter 2026 results front and center for investors, highlighting higher RYTELO revenue, a smaller net loss and reaffirmed full year guidance as the core of the latest update. See our latest analysis for Geron. Despite the Q1 beat and reaffirmed guidance, Geron’s recent share price performance has been weak, with a 30 day share price return of 16.1% and a 7 day share price return of 5.2%. The 1 year total shareholder return of 15.9% contrasts with a 3 year total...
Geron Corporation (NASDAQ:GERN) Just Reported And Analysts Have Been Lifting Their Price Targets
Geron Corporation ( NASDAQ:GERN ) just released its latest quarterly results and things are looking bullish. Revenues...
Geron Corporation Q1 2026 Earnings Call Summary
Moby summary of Geron Corporation's Q1 2026 earnings call
Geron Q1 Earnings Call Highlights
Geron (NASDAQ:GERN) reported first-quarter 2026 net revenue of $61.8 million, up 31% year-over-year and 8% quarter-over-quarter, as the company continued to scale commercialization of Rytelo in the U.S. Management reiterated full-year 2026 guidance and outlined ongoing work to evaluate a European co